Academic Drug Discovery

Date: Monday, 6 March 2017 - Tuesday, 7 March 2017
Location: Wellcome Genome Campus Conference Centre, Cambridge, UK

Keynote Speakers

Michelle Arkin
Director of the Small Molecule Discovery Center, University of California San Francisco

Sir Alan Fersht
Professor, MRC Laboratory of Molecular Biology

Paul Workman
Chief Executive and President, Institute of Cancer Research, London

Overview

SELECTBIO is thrilled to announce the continuation of Academic Drug Discovery for 2017!

Owing to the success of the conference in 2015 and 2016, this will now form part of a larger, multi-track event, with Antibodies in Drug Discovery, Epigenetics in Drug Discovery and Stem Cells in Drug Discovery, all held at the Wellcome Genome Campus Conference Centre on Monday 6th and Tuesday 7 March 2017 in Cambridge, UK. Attendees will benefit from unrestricted access to all four conference tracks.

In recent years pharmaceutical companies have moved away from conducting early-stage preclinical research in-house and are instead partnering with academic institutions to pursue programmes around emerging targets. This has resulted in significant opportunities for academic-based drug discovery and development centres.

Attracting a global audience of researchers, group leaders, directors and heads of leading academic and open innovation drug discovery centres, this event will explore the current challenges and opportunities faced in academic drug discovery. Topics covered include Open Innovation, Successful Partnering Models for Academia and Industry, Fragment Based Drug Discovery, New Lead Identification, Lead Optimisation and Medicinal Chemistry.

If you work in drug discovery research you will benefit from the expert knowledge and insights provided by key opinion leaders who are successfully implementing collaborations between academia and industry.

SELECTBIO is offering a limited number of student bursaries at this event. Find out more

Agenda Topics

Fragment Based Drug Discovery
Lead Optimisation
Medicinal Chemistry
New Lead Identification
Open Innovation
Successful Partnering Models for Academia and Industry

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Per Arvidsson, Director, Karolinska Institutet
James K Bashkin, Professor, University of Missouri–St. Louis
Sonal Das, Senior Manager, Corporate Development and Strategy, Biogen
Robert Don, Discovery & Preclinical Director, Drugs for Neglected Diseases
Stuart Farrow, Director of Biology, Cancer Research Technology
Nancy Federspiel, Associate Director Of The Spark Translational Research Program, Stanford University School of Medicine
Paul Fish, Head of Chemistry, Alzheimers Research UK, UCL Drug Discovery Institute
Kamyar Hadian, Group Leader, Helmholtz Zentrum München
Tim Hammonds, Deputy Director Drug Discovery, Cancer Research Technology
Roderick Hubbard, Professor/Senior Fellow, University of York
Eric Marsault, Professor, University of Sherbrooke
Chris Molloy, CEO, Medicines Discovery Catapult
Mark Moloney, Professor of Chemistry, University of Oxford
Susanne Muller Knapp, Group Head Structural Genomics Consortium (SGC), University Of Oxford
Adam Nelson, Professor, Leeds University
Gemma Nixon, Lecturer, University of Liverpool
Barry Potter, Professor, University Of Oxford
Kevin Read, Head-DMPK, University of Dundee
Gemma Ryder, Product Marketing Manager, Adis Business Intelligence , Springer Nature
Malcolm Skingle, Director, Academic Liaison, GlaxoSmithKline
Edgar Specker, Head of Compound Management, Medicinal Chemistry Group, Leibniz Institute of Molecular Pharmacology
John Spencer, Professor, University of Sussex